丽珠集团莱康奇塔单抗注射液被纳入优先审评审批程序

Core Viewpoint - The company has successfully entered the priority review process for its product, indicating a significant advancement in its drug development pipeline [1] Group 1: Company Development - The company's subsidiary, Zhuhai Lizhu Antibody Biotechnology Co., Ltd., has collaborated with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. to develop the product, Lakanqita Monoclonal Antibody Injection [1] - The product was included in the list of drugs for priority review by the National Medical Products Administration (NMPA) on December 26, 2025, and has now officially entered the priority review approval process [1]